The landscape of healthcare financing in India is undergoing a significant transformation, driven by innovative companies leveraging technology to make healthcare more accessible and affordable. Leading the charge are several key players who offer specialized financial solutions tailored to the unique needs of the healthcare sector. From providing interest-free loans and fast-tracked insurance claim processing to enabling the purchase of state-of-the-art medical equipment and offering flexible payment options for patients, these companies are reshaping the way healthcare is funded. This article highlights some of the pioneering organizations that are revolutionizing healthcare finance in India, ensuring that quality medical care is within reach for all.
DigiSparsh is revolutionizing healthcare financing in India with its pioneering FinTech platform, designed to make healthcare accessible and affordable for all. The company offers comprehensive financial services across the healthcare ecosystem, including interest-free loans and claim servicing for patients, bill discounting against insurance receivables for hospitals, and supplier financing for merchants. Additionally, their innovative Tatk@@l service allows patients using cashless facilities to be discharged from hospitals within 60 seconds of bill preparation, eliminating the typical 4-8 hour wait for insurance approval. With a vision to provide accessible healthcare through financial solutions and a mission to leverage cutting-edge technology, DigiSparsh is transforming the landscape of healthcare finance in India.
Policybazaar.com is one of India's largest digital insurance platforms and the flagship platform of PB Fintech, which also owns the fintech brand Paisabazaar.com and the lending and insurance marketplace Policybazaar.com in the UAE region. Backed by numerous investors, including PE funds and family offices, Policybazaar.com was established to educate people on insurance products and has effectively addressed the large and highly underpenetrated online insurance market. With a mission to build a safety net for households in India and a vision of creating a healthy and well-protected nation, Policybazaar.com is a leading player in the healthcare finance landscape.
Fibe (formerly EarlySalary) is a leading consumer lending app in India, catering to young, tech-savvy professionals. Initially launched to address short-term cash crunches, Fibe now offers a wide range of financial products, including specialized healthcare financing.
Fibe’s healthcare finance program provides up to INR 10 lacs for top-quality medical care without the burden of immediate costs. The funds are directly credited to healthcare providers, offering low-cost or interest-free EMIs. With flexible repayment terms and no foreclosure charges, Fibe ensures healthcare remains accessible and affordable during life’s challenging moments.
Committed to economic empowerment and fulfilling the aspirations of young India, Fibe continues to expand its reach and impact, making healthcare financing seamless and stress-free for all.
Clix Capital stands out as a leading force in healthcare financing, revolutionizing the lending landscape with its digital prowess. Led by CEO Rakesh Kaul, Clix Capital offers tailored financial solutions, including healthcare equipment finance, to meet the evolving needs of the sector. With a focus on advanced technology and analytics, Clix Capital has transitioned into a retail-focused entity, serving over 3 million customers across India. The company provides loans of up to INR 15 crores to healthcare institutes and practicing doctors with competitive interest rates. They offer both loans and leasing solutions for new, refurbished, and used medical equipment, with long tenures and high Loan-to-Value (LTV) ratios. Clix Capital operates without geographical limits, funding healthcare professionals nationwide. Their exclusive Fast Track Programs offer fast track sanction within 24 hours for loans up to INR 1 crore, with minimal documentation required. Clix Capital’s proactive measures to mitigate portfolio stress and reduce non-performing assets underscore its commitment to responsible lending practices. Backed by strategic partnerships and a robust platform, Clix Capital is poised to expand its footprint in healthcare financing, driving accessibility and affordability in the sector. Through healthcare equipment loans, Clix Capital enables medical professionals to access the latest technology, ensuring modern equipment and world-class care for patients across India.
InsuranceDekho, founded in 2017 by Ankit Agarwal, has rapidly emerged as a leader in the Indian Insurtech landscape, transforming the insurance sector with its innovative, AI and ML-powered digital platform. The company aims to simplify insurance processes, making it more accessible to millions across the nation. With over 8 million customers served and insuring 21 Indians every minute. Headquartered in Gurugram, InsuranceDekho offers a comprehensive range of insurance products, including health, motor, life, travel, and pet insurance, in partnership with over 48 insurance companies. The platform not only provides extensive coverage options but also boasts a robust support system, including 24x7 claims assistance. Through its ID Academy, the company empowers a vast network of agents, significantly enhancing their income and fostering economic independence, particularly among women. Recognized for its excellence, InsuranceDekho continues to innovate and expand.
SaveIN is a fast-growing healthcare fintech company that helps people split their medical expenses into easy monthly instalments at private healthcare practices.
The core challenge it aims to address is the financial burden faced by millions of Indians when it comes to planned or unplanned medical treatments. Currently, over 90% of Indians lack private healthcare insurance, leading to over 75% out of pocket expense towards healthcare. Furthermore, even those with private healthcare coverage often find themselves inadequately covered in terms of treatments and products, as many crucial services remain outside the scope of traditional healthcare insurance.
Additionally, medical inflation in India is 15% per annum, thereby making paying for private healthcare prohibitively expensive and frictional for many.
As Indians look to prioritize personal health and wellness, SaveIN’s unique approach of creating an end-to-end system for availing private care without breaking the bank may just be the solution needed both by customers and medical practices alike.
Disclaimer: The following list is based on our research and survey and is not ranked according to the performance of the companies. While this feature highlights specific organizations, many other organizations are playing a crucial role in healthcare financing.
The landscape of healthcare financing in India is undergoing a significant transformation, driven by innovative companies leveraging technology to make healthcare more accessible and affordable. Leading the charge are several key players who offer specialized financial solutions tailored to the unique needs of the healthcare sector. From providing interest-free loans and fast-tracked insurance claim processing to enabling the purchase of state-of-the-art medical equipment and offering flexible payment options for patients, these companies are reshaping the way healthcare is funded. This article highlights some of the pioneering organizations that are revolutionizing healthcare finance in India, ensuring that quality medical care is within reach for all.
DigiSparsh is revolutionizing healthcare financing in India with its pioneering FinTech platform, designed to make healthcare accessible and affordable for all. The company offers comprehensive financial services across the healthcare ecosystem, including interest-free loans and claim servicing for patients, bill discounting against insurance receivables for hospitals, and supplier financing for merchants. Additionally, their innovative Tatk@@l service allows patients using cashless facilities to be discharged from hospitals within 60 seconds of bill preparation, eliminating the typical 4-8 hour wait for insurance approval. With a vision to provide accessible healthcare through financial solutions and a mission to leverage cutting-edge technology, DigiSparsh is transforming the landscape of healthcare finance in India.
Policybazaar.com is one of India's largest digital insurance platforms and the flagship platform of PB Fintech, which also owns the fintech brand Paisabazaar.com and the lending and insurance marketplace Policybazaar.com in the UAE region. Backed by numerous investors, including PE funds and family offices, Policybazaar.com was established to educate people on insurance products and has effectively addressed the large and highly underpenetrated online insurance market. With a mission to build a safety net for households in India and a vision of creating a healthy and well-protected nation, Policybazaar.com is a leading player in the healthcare finance landscape.
Fibe (formerly EarlySalary) is a leading consumer lending app in India, catering to young, tech-savvy professionals. Initially launched to address short-term cash crunches, Fibe now offers a wide range of financial products, including specialized healthcare financing.
Fibe’s healthcare finance program provides up to INR 10 lacs for top-quality medical care without the burden of immediate costs. The funds are directly credited to healthcare providers, offering low-cost or interest-free EMIs. With flexible repayment terms and no foreclosure charges, Fibe ensures healthcare remains accessible and affordable during life’s challenging moments.
Committed to economic empowerment and fulfilling the aspirations of young India, Fibe continues to expand its reach and impact, making healthcare financing seamless and stress-free for all.
Clix Capital stands out as a leading force in healthcare financing, revolutionizing the lending landscape with its digital prowess. Led by CEO Rakesh Kaul, Clix Capital offers tailored financial solutions, including healthcare equipment finance, to meet the evolving needs of the sector. With a focus on advanced technology and analytics, Clix Capital has transitioned into a retail-focused entity, serving over 3 million customers across India. The company provides loans of up to INR 15 crores to healthcare institutes and practicing doctors with competitive interest rates. They offer both loans and leasing solutions for new, refurbished, and used medical equipment, with long tenures and high Loan-to-Value (LTV) ratios. Clix Capital operates without geographical limits, funding healthcare professionals nationwide. Their exclusive Fast Track Programs offer fast track sanction within 24 hours for loans up to INR 1 crore, with minimal documentation required. Clix Capital’s proactive measures to mitigate portfolio stress and reduce non-performing assets underscore its commitment to responsible lending practices. Backed by strategic partnerships and a robust platform, Clix Capital is poised to expand its footprint in healthcare financing, driving accessibility and affordability in the sector. Through healthcare equipment loans, Clix Capital enables medical professionals to access the latest technology, ensuring modern equipment and world-class care for patients across India.
InsuranceDekho, founded in 2017 by Ankit Agarwal, has rapidly emerged as a leader in the Indian Insurtech landscape, transforming the insurance sector with its innovative, AI and ML-powered digital platform. The company aims to simplify insurance processes, making it more accessible to millions across the nation. With over 8 million customers served and insuring 21 Indians every minute. Headquartered in Gurugram, InsuranceDekho offers a comprehensive range of insurance products, including health, motor, life, travel, and pet insurance, in partnership with over 48 insurance companies. The platform not only provides extensive coverage options but also boasts a robust support system, including 24x7 claims assistance. Through its ID Academy, the company empowers a vast network of agents, significantly enhancing their income and fostering economic independence, particularly among women. Recognized for its excellence, InsuranceDekho continues to innovate and expand.
SaveIN is a fast-growing healthcare fintech company that helps people split their medical expenses into easy monthly instalments at private healthcare practices.
The core challenge it aims to address is the financial burden faced by millions of Indians when it comes to planned or unplanned medical treatments. Currently, over 90% of Indians lack private healthcare insurance, leading to over 75% out of pocket expense towards healthcare. Furthermore, even those with private healthcare coverage often find themselves inadequately covered in terms of treatments and products, as many crucial services remain outside the scope of traditional healthcare insurance.
Additionally, medical inflation in India is 15% per annum, thereby making paying for private healthcare prohibitively expensive and frictional for many.
As Indians look to prioritize personal health and wellness, SaveIN’s unique approach of creating an end-to-end system for availing private care without breaking the bank may just be the solution needed both by customers and medical practices alike.
Disclaimer: The following list is based on our research and survey and is not ranked according to the performance of the companies. While this feature highlights specific organizations, many other organizations are playing a crucial role in healthcare financing.
Pattom Sree Uthradam Thirunal Hospital, commonly known as SUT Hospital, has been a beacon of modern healthcare in Thiruvananthapuram for over three and a half decades. Established in 1987, this multi-specialty hospital has not only filled a crucial healthcare gap in the region. Still, it has also emerged as a pioneering force in providing tertiary & quaternary care services. Founded by Dr. C Bharath Chandran an eminent cardiologist during its inception and fortified by the unwavering commitment of the clinical and support fraternity the hospital has emerged as a stalwart in the realm of healthcare, etching a narrative of unparalleled excellence in treatment and care. Under the visionary guidance of Chairman B R Shetty, SUT Hospital has ascended to unparalleled heights as a healthcare provider par excellence. Collaborative efforts by all concerned have proven pivotal in not just navigating but propelling the hospital toward the zenith of excellence. Under his guidance, the hospital has evolved into a dynamic institution that seamlessly blends state-of-the-art medical advancements with a human touch, creating an environment where patients not only heal but flourish.
SUT Hospital's journey began with a commitment to innovation. In its early years, the institution achieved several groundbreaking milestones, including hosting Kerala's first beating heart surgery and performing the first complicated mitral valvuloplasty within three years of its inception. These achievements underscore SUT's dedication to pushing the boundaries of medical science and providing state-of-the-art treatments.
Col. Rajeev Mannali: Leading SUT Pattom Super Speciality Hospital to New Heights
Col. Rajeev Mannali’s illustrious journey from a decorated military officer to a pioneering healthcare leader is a testament to his unwavering dedication and multifaceted expertise. As the Executive Director of SUT Pattom Super Speciality Hospital, Col. Mannali has been instrumental in steering the institution towards unprecedented success and innovation. Under his leadership, the hospital has seen a remarkable transformation, solidifying its reputation as a premier healthcare provider.
His leadership has not only improved operational efficiency but also enhanced patient care, earning the hospital recognition from esteemed organizations such as 'Ayurarogyam' and 'Kalakaumudi'. His visionary approach continues to elevate SUT Pattom, setting new benchmarks in healthcare delivery.
CEO Col. Rajeev Mannali emphasizes SUT's commitment to providing affordable treatment, highlighting that the hospital has not increased the cost of treatment in the last five years. Despite challenges such as fluctuating exchange rates and the need to replace sophisticated medical equipment, SUT continues to prioritize cost-effectiveness, ensuring that high-quality healthcare remains accessible to the common man. The hospital ardently adheres to the principle of “Pulse before Purse” enunciated by the Chairman, Dr. B R Shetty
SUT Hospital boasts more than 30 specialty departments, including cardiac science, neuroscience, Gastro surgery, plastic surgery, urology, nephrology, OBG, and vascular surgery. The hospital's 24-hour emergency and trauma care services further solidify its position as a comprehensive center of care. From its humble beginnings with less than 100 beds, SUT has grown to a 200-bed hospital with seven state-of-the-art operations theatres and 67 ICU beds.
Under the neuroscience department, SUT has established a flourishing center of excellence, earning recognition for outstanding contributions to stroke care. Dr. Thomas Iype, Head of the Neurology Department, received the “Best Stroke Care Provider of the Year” Award in October 2023 from Voice of Healthcare an NGO at the national level. Additionally, SUT's commitment to ethical clinical practice is fairly well acknowledged.
SUT Hospital's commitment to excellence has been acknowledged through various prestigious awards. The hospital received the “Excellence in Healthcare Award” from the Honorable Governor, Sri. Arif Muhammed Khan. The hospital was also honored as the “Best Multi Super Specialty Hospital in Kerala” at the Worldwide Achievers Award ceremony where the honors were done by Sri. S P Singh Baghel, Honorable Union Minister of State for Health & Family Welfare. Furthermore, Outlook Business recognized SUT as the 'Brand of the Year in Healthcare' during their SPOTLIGHT program in Mumbai in December 2023.
SUT is not just a healthcare provider but is also a recognized training center approved by the American Heart Association, offering courses in Basic Life Support (BLS), Advanced Cardiovascular Life Support (ACLS), and ‘Heart Saver’ courses. SUT ensures high-quality training with in-house AHA-licensed instructors and faculties.
From its inception, the organization has woven a culture of quality into its fabric, a commitment echoed and substantiated by its esteemed certification from the National Accreditation Board for Hospitals & Healthcare Providers (NABH), ensuring patients receive care that not only heals but also upholds the highest ethical standards. SUT is an “Adverse Drug Reaction Monitoring Center”, approved by the Pharmaco Vigilance Program of India. SUT's exceptional dedication to Mother and Baby care has garnered the prestigious Mother & Baby Friendly Hospital accreditation (MBFHI), with an impressive score of 99.03%, the second highest in the state, SUT is recognized as a haven for newborns and mothers.
SUT's Institutional Ethics Committee for Human Subject Research achieved a significant milestone in January 2024 by obtaining approval from both the Indian Council of Medical Research (ICMR) and the Department of Health Research (DHR). This recognition reaffirms SUT's dedication to conducting ethical research in the healthcare sector.
In conclusion, SUT Hospital stands as a beacon of healthcare excellence. Its pioneering spirit, commitment to affordability, diverse specialties, and numerous accolades collectively shape the healthcare landscape. Beyond Kerala, SUT continues to influence and redefine healthcare standards, exemplifying a legacy of unwavering dedication to excellence.
ResMed is a global leader in digital health and cloud-connected medical devices helping people with chronic diseases. Our digital health technologies and cloud-connected medical devices transform care for people with sleep Apnea, COPD, and other chronic diseases.
ResMed’s mission is to empower people to live happier, healthier, and higher-quality lives in the comfort of their home or setting of their choice.
Our company’s comprehensive out of hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. ResMed also assists people seeking out of hospital care and promotes healthy living by enabling them to sleep and breath better, allowing them to live healthier and higher quality lives in more than 140 countries.
With a focus on CPAP therapy, ResMed is renowned for its expertise in addressing conditions like sleep Apnea, Chronic Obstructive Sleep Apnea (COPD) and other respiratory conditions. It also offers remote monitoring through SaaS solutions.
In addition to CPAP therapy, ResMed offers a variety of other respiratory care solutions and sleep screening tools. ResMed has developed cloud-based platforms, such as AirView and MyAir, which enable healthcare providers to remotely monitor and manage their patients' therapy data.
ResMed is tirelessly working towards building digital or cloud-based solutions for the treatment of sleep and respiratory disorders and has globally changed the lives of over 170+ million people in the last 12 months with 23.5+ million cloud connected devices. (as of December 2023).
ResMed has served 140+ countries as part of its efforts to develop and maintain patient care. In order to improve patient care, we have collected and examined more than 17+ billion nights of medical sleep and respiratory data.
As a market, India is a dynamic and ever-changing one. Investigating the underdiagnosed epidemic of sleep health and disorders in India is crucial, as the country works to improve patient care and operational effectiveness in the healthcare sector.
Despite the growing availability of digital healthcare services, some Indians remain hesitant to embrace them due to concerns surrounding data security and privacy, underscoring the importance of fostering trust and accessibility in these platforms.
Our ResMed Sleep Survey 2024 also highlights how only 27% of the Indian respondents are getting a good night's sleep across both quality and quantity every day of the week highlighting the need to educate the public about sleep hygiene. With cutting-edge digital health solutions, ResMed continues to work towards promoting sleep awareness in India and empowering both individuals and the medical community with our devices and awareness campaigns.
We believe that the Indian market will continue to evolve and develop thanks to ongoing development and lifestyle changes amongst Indians. In line with our mission to help people breathe and live better lives, our business strategies will continue to evolve to ensure we continue to be best placed to help Indians live better.
At the same time, there is a segment of the population who continue to be underserved and as a result underpenetrated. With the growth and expansion of digital healthcare in India, we are expanding the cornerstone of digital health technology and introducing SaaS solutions in out-of-hospital care settings to transform out-of-hospital (OOH) healthcare by boosting clinical decision support and facilitating better patient care. Readmissions to hospitals and outpatient visits are significantly reduced by remote patient monitoring.
India is a market that holds a lot of opportunity for ResMed as well. With this in mind, we set up our technology centre, ResMed Technology India Pvt Ltd. In Bengaluru in 2023.
We have also conducted sleep surveys in India over the years where we have noticed a concerning trend that highlights a critical need for greater education on sleep health and hygiene, including the importance of seeking medical help for sleep-related conditions.
We further advocate for the classification of noncommunicable diseases (NCDs) to include sleep-related conditions like Obstructive Sleep Apnea (OSA) and sleep testing should be included as part of the National Diagnostics Essential List's category of diagnostics. This would not only be consistent with the progressive trend of the healthcare sector, but it would also increase Indians' access to these vital services.
“We believe that the Indian market will continue to evolve and develop thanks to ongoing development and lifestyle changes amongst Indians. In line with our mission to help people breathe and live better lives, our business strategies will continue to evolve to ensure we continue to be best placed to help Indians live better.” Sandeep Gulati, General Manager, South Asia, ResMed.
Tricog, a pioneering healthcare technology Company, has redefined India's public health landscape with its comprehensive approach to Cardiovascular disease management, particularly targeting ST-elevation Myocardial Infarction (STEMI). Through innovative telemedicine solutions, Tricog bridges healthcare accessibility gaps, enabling remote consultations and real-time communication among stakeholders. Seamless integration of electronic health records provides a holistic patient view, enhancing diagnostic accuracy and treatment efficacy.
Based in Bangalore, Tricog Health is dedicated to curbing premature deaths caused by Heart Attacks. Its multifaceted strategy includes remote 12 Lead ECG acquisition, AI-powered specialist reporting with STEMI alarms, and advanced care coordination platforms, ensuring timely interventions within the critical golden hour. Moreover, Tricog strengthens health systems through training initiatives and robust monitoring systems, aligning with national guidelines set by the Ministry of Health and Family Welfare. Tricog's impact extends across various states, including Goa, Karnataka, Maharashtra, Telangana, and Odisha, where its solutions have played a pivotal role in bolstering the National STEMI Program and transforming public health outcomes.
Tricog's InstaECG platform stands at the forefront of cardiovascular care innovation, leveraging cutting-edge AI algorithms to deliver swift and accurate analysis of ECG readings. Tailored for emergency scenarios, this cloud-based system empowers healthcare providers with remote access to ECG reports, particularly valuable in regions lacking specialized medical expertise. Through seamless integration with telemedicine services, Tricog facilitates remote consultations, enhancing patient outcomes and communication, especially in underserved areas.
Key features of Tricog's approach to ECG analysis include advanced AI algorithms for rapid interpretation, cloud-based infrastructure enabling remote access to reports, seamless integration with telemedicine services, scalability for widespread adoption, and a focus on emergency care settings. The efficacy of Tricog's InstaECG platform is exemplified in its deployment in ST Elevation Myocardial Infarction (STEMI) programs across various Indian states, yielding positive outcomes and contributing to reduced mortality rates. Beyond India, Tricog's global footprint extends to countries like the Philippines, Kenya, Singapore, and the USA, solidifying its position as a leader in cardiovascular healthcare solutions.
Tricog's groundbreaking platform, InstaECG, has made a significant impact on public health, particularly in Cardiovascular Disease (CVD) management, aligning with global health objectives like the United Nations Sustainable Development Goals (UN SDG) 2030 and Universal Health Coverage. Its robust features and successful implementations have addressed critical healthcare challenges, resulting in improved patient outcomes and healthcare delivery.
Deployed across multiple states, Tricog's InstaECG platform has demonstrated remarkable effectiveness in early detection and seamless integration of CVD management into existing healthcare systems. In Odisha, Telangana, Goa, Maharashtra, and Karnataka, the platform has detected thousands of STEMI cases with impressive turnaround times, ranging from 4 to 6 minutes on average. These initiatives cover large populations and have contributed to reducing mortality rates by facilitating timely interventions.
Tricog's commitment to public health is evident through its extensive deployment in various states and pilot projects in regions like Jammu and Kashmir, Himachal Pradesh, Assam, Haryana, and Uttar Pradesh. By leveraging technology to establish an end-to-end system of care for CVD detection and management, Tricog has received acclaim from healthcare professionals and communities alike for its role in saving lives through early diagnosis and triaging.
During development, securing substantial capital posed a significant hurdle. Innovating in healthcare devices demands considerable financial investment, and Tricog required external funding to bring the InstaECG to fruition. Fortunately, strategic partnerships with external investors who shared Tricog's vision provided the necessary backing. This support not only alleviated initial capital barriers but also underscored confidence in Tricog's capabilities, propelling its progress in the market.
Transitioning to implementation, Tricog encountered resistance to the adoption of its platform within the healthcare ecosystem. Despite its innovation, convincing stakeholders of the InstaECG's value proved challenging. To address this, Tricog focused on building a pan-India network and fostering relationships with key opinion leaders. Through relentless efforts to showcase reliability and benefits, Tricog gradually gained recognition and acceptance. Today, the InstaECG stands as a testament to Tricog's perseverance, strategic alliances, and unwavering commitment to overcoming obstacles in its mission to revolutionize healthcare.
Tricog has reached a pivotal juncture in its evolution, with its innovative technology platform proving highly effective in promptly detecting cardiovascular cases. Building on this achievement, Tricog is now poised to advance to the next stage by transitioning from detection to early prediction of cardiovascular conditions. This marks a significant leap forward in triaging and treating cardiovascular cases.
With a clear strategic direction, Tricog is preparing to introduce several new product segments in the digital healthcare arena. These offerings will harness the extensive data amassed throughout Tricog's journey to date. By leveraging this data, Tricog aims to develop a platform capable of accurately predicting cardiac conditions at an early stage. This proactive approach has the potential to greatly enhance opportunities for prevention and treatment, ultimately leading to more lives saved.
The envisioned platform will not only facilitate the early identification of cardiac issues but also enable better-informed decision-making for healthcare providers. By equipping clinicians with predictive insights, Tricog seeks to improve the effectiveness of treatment strategies and optimize patient outcomes.
Trivitron Healthcare is a global MedTech organization dedicated to making medical technologies accessible worldwide. Our mission is to provide innovative healthcare solutions at competitive prices, ensuring everyone has access to essential medical care, regardless of location or financial status. Through our commitment to accessibility, we strive to improve healthcare outcomes and positively impact the lives of millions around the world.
Trivitron Healthcare, a pioneer in MedTech, manufactures a wide array of devices including CT scanners, mammography systems, X-ray and ultrasound imaging, alongside advanced newborn screening technology, and others. With a strong emphasis on the "Make in India" initiative, we're committed to enhancing diagnostic precision and therapeutic outcomes. Our robust R&D and manufacturing capabilities allow us to create superior, precise, reliable medical technology solutions, ensuring our products meet the highest standards of quality and innovation. This approach not only propels domestic production but also positions us as a leader in global healthcare technology.
Trivitron Healthcare's innovations have revolutionized patient care and healthcare delivery, from critical care to catheterization laboratories and diagnostics. Our commitment to high-quality manufacturing practices ensures that our technologies, such as CT Scanners, portable ultrasound machines and radiation protection gears and accessories, continually evolve to meet clinical needs. These advancements facilitate precise diagnoses and safer treatment environments, significantly enhancing both patient outcomes and the operational efficiency of healthcare systems worldwide.
The journey to bring our innovations to life involved surmounting numerous challenges, including complex technical hurdles, dependency on imports, stringent regulatory landscapes, finding skilled workforce, and shifting market dynamics. Trivitron Healthcare overcomes these obstacles through strategic foresight, robust collaboration across teams, and unwavering commitment to innovation. This proactive approach enabled us to deliver cutting-edge healthcare solutions efficiently and effectively, ensuring we meet the highest expectations based on the market demands and contribute positively to medical science and patient care.
At Trivitron Healthcare, we envision a future where healthcare is empowered by innovation and technology, inspired by our commitment to excellence. Our vision encompasses pioneering Make in India CT scanners, expanding Next Generation Sequencing technologies (genomics & proteomics), integrating AI-driven solutions across Imaging, Critical Care, Diagnostics, Newborn Screening, and Cath labs. We strive to harness the transformative potential of data and technology to enrich global healthcare delivery and enhance patient outcomes. We are focused to shape a future where patient-centric care converges seamlessly, ensuring healthier lives worldwide.
Roche is the world’s largest biotech company. Roche Diagnostics India Pvt. Ltd. established in the year 2002 has offices located in Chennai, Delhi, Kolkata and Mumbai with over 400 employees. Our broad range of innovative diagnostic tests and systems play a pivotal role in the groundbreaking area of integrated healthcare solutions and cover early detection, targeted screening, evaluation, and disease monitoring. Roche Diagnostics India works with the objective of “Doing now what patients need next”, thus preparing for the nation’s future healthcare needs.
Roche Diagnostics India has redefined the landscape of in vitro diagnostics, setting new standards for precision, efficiency, and patient care. The company’s cutting-edge diagnostic technologies have not only transformed the way we approach clinical testing but also set new standards for precision and reliability.
Among its groundbreaking achievements is the introduction of Nucleic acid testing (NAT) for blood safety, a pioneering initiative addressing the critical need for safe blood in India. Through centralised NAT testing, Roche enables blood banks to ensure the safety of blood donations, with over 1.2 million donations tested in 2023 across 64 NAT sites. This triple-win approach enhances accessibility to safe blood, mitigating risks and saving lives.
In the fight against cervical cancer, Roche's cobas® HPV test emerges as a game-changer. This test aligns with WHO guidelines for cervical cancer elimination.
Roche continues to lead innovation with the world's first Alzheimer's CSF test, Elecsys AD CSF, empowering physicians with a reliable tool for early diagnosis. With its widespread availability in prestigious institutions across India, including AIIMS Hospital and Apollo Hospital, this test addresses the critical need for accurate Alzheimer's diagnosis in a country burdened by millions of new cases annually.
Moreover, its affordability compared to PET Amyloid testing makes it accessible to a broader population, revolutionizing Alzheimer's disease management.
Further enhancing diagnostic capabilities, Roche introduces the HCV Duo test, a breakthrough in hepatitis C virus detection. By enabling simultaneous determination of antigen and antibody status, this test facilitates earlier diagnosis, leading to timely intervention and improved patient outcomes. Validated through rigorous studies, including collaboration with Metropolis Labs, the HCV Duo test simplifies diagnostic algorithms, reducing patient burden and streamlining healthcare delivery.
In essence, Roche Diagnostics India epitomizes excellence in technological advancement and healthcare innovation. With a steadfast commitment to shaping a future where healthcare knows no bounds, Roche is driving progress and inspiration in the field of in vitro diagnostics and digital healthcare. Through its transformative solutions, Roche is not just revolutionizing healthcare—it's revolutionizing lives.
Vision: We envision a future where life-changing innovation reaches every individual in need. We firmly believe that access is the cornerstone of meaningful progress in healthcare. Our vision is to ensure that our diagnostic solutions are accessible to all, revolutionizing patient care and improving lives.
Mission: At Roche Diagnostics, our mission is twofold. First, we strive to lead the way in developing diagnostic solutions that empower healthcare professionals to make critical decisions for patient well-being. Second, we are committed to seamlessly integrating these essential tools into global health systems, while reducing costs and maximising outcomes. Through our dedication to accessibility and excellence, we aim to transform healthcare delivery and ensure that every individual receives the quality care they deserve.
In 2010, a team of seasoned professionals laid the foundation for Innvolution Healthcare, bringing together over 100 years of combined experience in the healthcare industry. Today, the organization stands as a leading provider of comprehensive cardiovascular solutions in India.
Specializing in products such as Cath Lab, Drug-eluting Stents, Balloon Catheters and Guidewires, Innvolution Healthcare is dedicated to delivering integrated cardiac care solutions. Its mission extends beyond providing products to democratizing cardiac care, ensuring it is accessible to a wider population.
Driven by focused expertise and innovation, Innvolution Healthcare aims to enhance cardiovascular health and well-being across India. The company's inception marked a commitment to address critical gaps in cardiac care accessibility and affordability, particularly in underserved urban areas.
Innvolution Healthcare originated from a profound realization: the urgent need for quality cardiac care in India's tier 2 and tier 3 cities. Recognizing a significant gap in access to life-saving procedures like Angiography and Angioplasty, especially in smaller urban centres, the founders were motivated by the sight of individuals traveling long distances for essential treatments.
Understanding that timely access to cardiac care can be a matter of life and death, Innvolution Healthcare embarked on a courageous mission to establish Cath labs in these overlooked regions. Their goal was simple yet monumental: to ensure residents could receive prompt and high-quality medical interventions without enduring exhausting journeys.
Moreover, the founders identified the challenge of excessive reliance on costly imports in the growing medical imaging sector. This dependence placed a heavy financial burden on patients, hindering their access to critical care. Sensing an opportunity to transform this landscape, Innvolution Healthcare set out to localize and enhance India's cardiac care infrastructure, making it more cost-effective and accessible.
Innvolution Healthcare stands out in the healthcare sector by providing cutting-edge cardiovascular solutions that redefine the boundaries of innovation. With an impressive lineup of products including the thinnest Drug-eluting Stents (DES) and the groundbreaking "Pinnacle" Cath Lab, the company showcases an unyielding dedication to excellence and progress.
Central to its unique value proposition is the diversity of solutions for cardiovascular care, supported by advanced medical imaging technologies and strategic partnerships. This distinctive approach not only cements Innvolution Healthcare's position as a frontrunner in the industry but also cultivates a devoted customer base attracted to its state-of-the-art offerings.
The company's steadfast focus on delivering advanced, high-quality solutions resonates strongly with customers in search of top-tier cardiac care. Through a commitment to continuous improvement and innovation, Innvolution Healthcare consistently surpasses customer expectations. Its distinctive value proposition, characterized by cutting-edge technology, adaptable solutions, and a pledge to excellence, plays a crucial role in both attracting and retaining satisfied customers in the competitive healthcare arena.
Innvolution Healthcare embarked on its remarkable journey in 2010, marking a decade of extraordinary achievements and pioneering advancements. The initial stages of this journey were marked by significant milestones, including the acquisition of distribution rights for Sapphire in 2010 and the launch of the proprietary brand in 2011.
The establishment of IITPL in 2016 represented a pivotal moment, bringing together unparalleled expertise in interventional cardiology consumables, X-ray imaging, and Cath Lab manufacturing. The pinnacle of Innvolution Healthcare's innovative trajectory was reached in 2018 with the introduction of the revolutionary "Pinnacle" Cath Lab, a milestone recognized with the prestigious Red Dot Award.
Subsequent milestones included the unveiling of the second-generation Pinnacle Agile in 2019, coinciding with the achievement of USD 12 million in net sales and recognition as a top medical device company by the Indian government. In 2022, the trajectory of success continued with the launch of the cutting-edge CE marked Premier Series Cath lab and the securing of series A funding from OrbiMed for further innovation.
Pride soared with the Frost and Sullivan Award for Best Practices, designating Innvolution Healthcare as the Indian Interventional Company of the Year. Additionally, being honored as the "World's Best Emerging Brand 2023" by WCRC INT at the prestigious House of Lords, The Palace of Westminster, added another layer of distinction to the journey.
Recently, Innvolution celebrated the shipment of its 300th Cath lab, reaffirming its steadfast commitment to innovation, as evidenced by the successful securing of series A funding from Orbimed.
The prestigious CE mark for the Pinnacle Agile and Premier Elite Cath Lab underscores their compliance with international standards, while the Best Brand 2023 Awards from the esteemed Economic Times further highlight the remarkable journey in healthcare innovation.
Innvolution Healthcare is renowned in the healthcare industry for its patient-centred approach, forward-thinking strategies, and technological expertise. By establishing Cath labs in tier 2 and tier 3 cities, the company addresses healthcare access disparities, especially for marginalized communities, by ensuring the availability of critical cardiac procedures. The leadership demonstrates agility by effectively balancing innovation with financial sustainability, while also fostering employee development and engaging stakeholders.
The company's commitment to affordability and accessibility is evident in its strategy of localizing services and reducing reliance on imports. This proactive approach makes high-quality cardiac care more financially feasible for a broader demographic.
In addition to immediate service delivery, Innvolution Healthcare contributes to community welfare by enhancing the overall cardiac care infrastructure in India. This comprehensive approach underscores the organization's leadership in innovation, patient well-being, and the advancement of healthcare standards.
Innvolution Healthcare's future trajectory is closely tied to the transformative potential of innovative technologies in healthcare. Gaurav's vision highlights the crucial role that technological advancements will play in shaping the organization's path as it navigates the changing healthcare landscape.
Leading this technological evolution are specific projects such as the vascular robotics project, tele echocardiography, Virtual-FFR, 3D rendering of the entire coronary tree, and Drug Eluting Balloons. These initiatives demonstrate our proactive engagement with cutting-edge technologies, showcasing our readiness to embrace advancements in vascular robotics, telemedicine, virtual reality-based interventions, and drug delivery technologies.
By integrating these technologies into our operations, Innvolution Healthcare is poised to excel in an era of rapid technological evolution in the healthcare sector. Aligned with our roadmap, the development of advanced features like Real-Time Stent Enhancement and the Dynamic Coronary Roadmap demonstrates our steadfast commitment to using technology to improve patient care.
Moreover, our collaborative efforts with academic institutions to explore augmented reality, virtual reality, robotics, and artificial intelligence underscore our dedication to staying at the forefront of technological advancements. Initiatives focused on AI and ML in imaging show our commitment to enhancing the safety and precision of therapies, while digital medicine initiatives, including remote disease diagnosis and therapy, highlight our forward-thinking approach to healthcare delivery.
The leadership's vision is to become the premier Cardiac Care solutions company, not only in India but also across Asia, setting an inspirational standard. Innvolution aspires to establish itself as a leader in the healthcare solutions sector. Over the next five years, the goal is to develop a comprehensive range of solutions, reducing dependence on imports while upholding the highest healthcare standards. There is a dedicated focus on enhancing India's self-sufficiency in X-ray equipment, with plans to introduce a Cath lab in each of India's 800 districts by 2030, a significant step toward decreasing the country's import expenditure.
The strategic roadmap includes pioneering innovations such as Real-Time Stent Enhancement, Dynamic Coronary Roadmap, Live QCA, tele-echocardiography, drug-eluting balloon, Virtual-FFR, and 3D rendering of the entire coronary tree. These innovations aim to improve precision and efficiency in complex medical procedures.
The vision extends beyond borders, aiming for a global presence in 20 countries across ASEAN, Latin America, Eastern Europe, and MENA. Supported by subsidiaries in Singapore, Dubai, Indonesia, and Brazil, alongside cutting-edge manufacturing facilities in Asia and Europe, the commitment to international growth and continuous innovation remains unwavering. Together, they are paving the way for a future where healthcare transcends boundaries.
Since our inception in 2016, Sunfox Technologies has been dedicated to our mission of saving lives through accessible and affordable technologies. Situated in the Himalayas, we specialize in developing cutting-edge healthcare solutions aimed at enhancing patient monitoring and diagnostics. Our flagship product, Spandan, a compact ECG device, has analyzed over 1 million heartbeats, leading to the saving of 100 thousand lives and the identification of 20 thousand critical cases. Our commitment extends to revolutionizing healthcare globally, ensuring that quality medical care reaches everyone, regardless of location or circumstance. Through relentless innovation, we strive to create a healthcare system that is more efficient, effective, and equitable for all.
Back in 2016, Sunfox Technologies proudly introduced its flagship product, Spandan ECG, paving the way for the future of heart health. With its cutting-edge 12-lead ECG machine, Spandan brings unparalleled power and precision to both personal and professional use. By revolutionizing cardiac diagnostics, Spandan offers a comprehensive ECG range, starting with the Spandan Legacy for swift evaluations and reports. Continuing its commitment to innovation, Spandan recently unveiled three new variants: Spandan Pro for clinical-grade ECG tests tailored for healthcare professionals, Spandan Neo for home heart care featuring sharp sensitivity and moisture resistance, and Spandan Military-Grade, specially crafted with durable features for our armed forces. With Spandan's portable 12-lead ECG Machine, identifying over 30 heart abnormalities becomes both swift and efficient, catering to everyone's needs. What's more, accessing medical-grade ECG tests on smartphones has never been more convenient, thanks to Spandan's innovative application software.
Sunfox's Spandan ECG was born from a deep-seated mission to combat heart problems head-on. Its unwavering dedication has earned international trust, with over 30,000 doctors integrating it into their practices and over 10,000 users benefiting from its home-use capabilities. Spandan has emerged as an indispensable tool, playing a pivotal role in addressing heart-related issues and proactively preventing heart attacks worldwide. In a remarkable display of commitment, Sunfox responded to escalating heart attack cases in Kedarnath by initiating complimentary ECG testing camps. Through these camps, over 300 critical cases were identified and promptly referred for urgent medical attention. Furthermore, Sunfox regularly conducts health camps in Uttarakhand and rural areas, ensuring seamless cardiac care for local residents. Patient care is further enhanced as individuals can perform ECG tests at home or on the go, saving them the hassle of frequent hospital visits. Through the revolutionary Spandan ECG, Sunfox Technologies has redefined the health-tech landscape, enabled early detection and saving lives globally by effectively preventing heart problems.
During the development of the Spandan ECG device, our team encountered its biggest challenge: achieving high accuracy. Convincing hospitals to allow us to conduct clinical trials was not easy as initially most of them showed resistance. But determined, we made our way through and Spandan achieved an accuracy of 99.7%, which is the highest in the portable ECG segment as of today. Yet, our journey didn't end there. Selling the product presented a fresh set of obstacles, as many were understandably hesitant to trust our innovation. To overcome this skepticism, we introduced a 10-day money-back guarantee, which we later extended to 20 days in some cases, to win over skeptics. Throughout this journey, we faced additional challenges in team building, recruitment, finance, and team management. Each obstacle was met with resilience and determination, driving us forward toward our ultimate goal. Today, we stand proud of our achievements, knowing that every challenge we overcame brought us one step closer to success.
Our vision for the future of healthcare technology is to create accessible solutions for all, ensuring that no precious life is compromised due to the lack of diagnostic devices. We aspire to reach every corner with our series of portable ECG solutions, uplifting communities at the grassroots level and establishing a robust healthcare ecosystem. As of now, we have impacted over 100,000 lives, and our commitment to increasing this number grows stronger each day. Nothing would bring us greater joy than to witness a world that is healthy and thriving. Our upcoming innovations will include even more high-tech portable ECG devices, further elevating cardiac care on a global scale.
FUJIFILM India Pvt. Ltd. Established in 2007 is a wholly owned subsidiary of FUJIFILM Holdings Corporation, Tokyo. FUJIFILM India is present in three business segments – Healthcare, Materials, and Imaging. With a vast portfolio of technologically advanced products, the company is involved in the business of Healthcare, Endoscopy Systems, Photo Imaging Solutions, Digital Still Camera, Instant Photo System (Instax), Optical Devises, Graphic Communication Solutions, Multifunction Printers, Recording Media & Industrial Product.
In the realm of healthcare, FUJIFILM India emerges as a frontrunner, specializing in diagnostic imaging systems, medical informatics solutions, and regenerative medicine technologies. With a rich history of innovation spanning nearly a century, Fujifilm's commitment in the healthcare domain is centered on elevating patient care and outcomes.
The mission in healthcare is underlined by a dedication to deliver state-of-the-art medical devices, AI-powered diagnostic tools, and digital health solutions. By empowering healthcare professionals with cutting-edge technologies, Fujifilm endeavors to enhance the efficiency and effectiveness of healthcare delivery, ultimately benefiting patients worldwide.
At the core of Fujifilm's ethos lie pillars of innovation, quality, and social responsibility. These principles propel the company to continually push boundaries and pioneer new technologies across various industries. Through relentless pursuit of innovation and unwavering commitment to quality and social welfare, Fujifilm remains at the forefront of addressing the challenges and seizing the opportunities presented by the modern world.
Fujifilm Technology's healthcare innovations encompass a wide array of cutting-edge devices and technologies aimed at revolutionizing diagnostic imaging, patient care, and clinical workflows. Here's a detailed overview of some of the notable advancements:
I. Digital Mammography Systems: Fujifilm AMULET Innovality digital mammography systems designed for early breast cancer detection offers high-resolution images coupled with ergonomic design and advanced image processing algorithms. The integration of AI technologies aids radiologists in interpreting images efficiently, leading to faster diagnoses and personalized treatment plans.
II. AI-driven Ultrasound Systems: The ARIETTA DeepInsight series ultrasound systems utilize AI for noise reduction, enhancing the quality of ultrasound imaging. This technology improves diagnostic accuracy and efficiency in ultrasound examinations.
III. Open MRI Technology: The APERTO Lucent is a cutting-edge Prime open MRI device that integrates IP-RAPID technology to reduce scan times while maintaining high image quality. This advancement ensures improved image quality with higher spatial resolution, offering swift scans and enhancing patient experience. The design prioritizes patient comfort with features like a True OPEN Bore design to reduce the risk of claustrophobia.
IV. Superconductive MRI System: Fujifilm’s Echelon Smart 1.5 Tesla MRI machine prioritizes patient comfort with acoustic noise reduction, operator-friendly operation support, and low power consumption. This system inherits high image quality from Fujifilm's technology and offers a flexible site layout inherited from permanent magnet MRI systems.
V. Advanced DEXA Machine: The FDX Visionary-DR DEXA machine integrates groundbreaking 3D-DXA technology, producing 3D femur models from routine bone-mineral-density images. Equipped with a 2D Fan Beam, it delivers high image resolution for precise diagnoses, conducting rapid assessments per site. This advancement aims to enhance diagnostic capabilities for bone-related diseases.
VI. Healthcare IT: RIS/PACS/VNA/3D- synapse for seamless digitisation of Radiology & workflow improvement.
VII. FDC - Dry chemistry analyzer delivers precise and rapid results without needing water, providing an environmentally-friendly green solution.
Overall, Fujifilm's healthcare innovations aim to improve patient outcomes, streamline clinical workflows, and advance medical practices through the integration of cutting-edge technologies and ergonomic design principles.
Fujifilm's healthcare innovations have empowered healthcare facilities with diagnoses that can help in early detection and patient care. The digital mammography solution is a cutting-edge state-of-art technology that has revolutionized early detection of breast cancer. By generating high-resolution images, they enable more precise diagnoses, empowering healthcare professionals to devise targeted treatment plans that can potentially save lives.
The integration of artificial intelligence (AI) into Fujifilm's medical imaging devices further amplifies their impact. With AI streamlining diagnostics, interpretation times are reduced, allowing for quicker treatment decisions. This not only improves patient outcomes but also enhances workflow efficiency, ensuring that individuals receive timely interventions when they need them most.
The APERTO Lucent, a Prime open MRI device, epitomizes Fujifilm's commitment to patient-centric care. Its advanced features, including reduced scan times and high image quality, enhance diagnostic accuracy and efficiency. Moreover, its patient-friendly design prioritizes comfort, making diagnostic processes less daunting for individuals. The device's compact design and simplified installation process also expand its reach, ensuring that advanced imaging technology is more accessible across various healthcare facilities.
FUJIFILM India stands as a significant force in healthcare technology, particularly in the realm of medical imaging, where their focus revolves around pushing the boundaries of diagnostic capabilities, enhancing patient outcomes, and optimizing healthcare delivery efficiency. Looking ahead, Fujifilm's future initiatives are poised to further revolutionize the landscape of healthcare technology in India.
Their roadmap includes the development of advanced medical imaging technologies such as CT, MRI, and ultrasound systems boasting improved resolution and faster scanning times. Additionally, they plan to harness the power of artificial intelligence (AI) for image analysis, facilitating quicker and more accurate diagnoses.
Innovation remains at the forefront of FUJIFILM India’s efforts wherein the strategic endeavors align closely with Fujifilm's core values of innovation and excellence in healthcare technology, promising advancements that hold the potential to benefit patients on a global scale.
In the fast-paced world of healthcare technology, few companies can boast a legacy as rich and enduring as Hindustan Syringes and Medical Devices (also known as HMD Healthcare), a stalwart presence in the medical device industry for over sixty-two years. Since their inception in 1957, the idea was to manufacture & market products of International Standard and offer them for the benefit of patients and doctors at prices that any other local manufacturer would find difficult to meet without compromising quality market leadership and consistency in mass production. HMD have been at the forefront of innovation, consistently delivering ground-breaking solutions that have transformed patient care and clinical outcomes.
The total installed capacity of the plants has been set up with a capital investment of over $100 Million USD and enhanced for a production capacity of more than 4.5 billion units per annum of disposables. More than 3500 plus employees and build up area over 20 acres, HMD is also distinguished by its culture of integrity, collaboration, and social responsibility.
One of the key pillars of Hindustan Syringes and Medical Device's success has been its unwavering commitment to quality and safety. Rigorous testing, stringent quality control measures, and adherence to regulatory standards have been integral to every stage of the company's product development process.
Over the years, HMD has revolutionized medical practices in India and beyond by launching innovative medical devices
Dispojekt Single Use Syringe with Safety Needles: HMD has recently launched the most innovative and first-of-its kind Dispojekt Syringes with Safety Needles in 2024, which further strengthens India's position in becoming global powerhouse in medical devices.
With the revolutionary Dispojekt safety needle syringes, HMD aims to reduce prevalence of accidental Needle Stick Injuries (NSIs) among health workers, reduction of infection control cost and that of disposal and training, offering a long term positive financial impact on the healthcare sector. Domestically manufacturing hi-tech product will provide India global edge in the realm of R&D and leapfrog indigenous players to meet the highly demanding global market for sharp injury prevention shield.
“Equipped with a safety shield, Dispojekt syringe addresses critical concerns of needle stick injuries and reaffirms our commitment as market leader towards excellence in healthcare. It is a great outcome of our Make in India resolve as envisioned by Prime Minister Narendra Modi to realize the goal of Viksit Bharat,” said Mr. Rajiv Nath, Managing Director, HMD, adding that India is all poised to become global powerhouse in manufacturing and exporting of medical devices in sync with the spirit of Aatmanirbhar Bharat.
Kojak Auto Disable Syringes: HMD’s earlier innovation was introduction of Kojak auto-disable (AD) syringes which are self-locking comes in a variety of options for different applications. Incorporated by a ring and break mechanism, which automatically breaks the plunger if a reuse of syringe is attempted. The reuse of Syringes leads to spread of blood borne infection and extended hospital stay. KOJAK helps address the issue globally and Countries like Uganda, Nigeria & Tanzania restricted import of Standard Disposable Syringes based on positive feedback of KOJAK.
HMD as possibly the world’s largest Manufacturer for Auto Disable syringes has achieved milestone of supplying 1.75 billion syringes of the total 13.3 billion Covid-19 vaccines administered globally, which means over 13% of covid shots administered worldwide was using Kojak Selinge AD Syringes. Nearly 1 covid vaccine in every 7-8 people worldwide was administered using HMD’s Kojak or Dispo Van syringe.
To ensure there is no shortage of syringes to help vaccinate India against Covid, HMD had supplied over 921.7 million syringes from Dec 2020 till April 2023 to the GOI to help vaccinate over 1 billion people to support the massive vaccination campaign to eradicate Covid-19 and help make India Aatmanirbhar.
Impact of this Innovation on Patient Care and Healthcare Delivery
Dispojekt safety needle syringes will give boost to our collective efforts to check NSIs (Needle Stick Injuries) leading to Hepatitis and HIV among healthcare workers, with an estimated 44.5 per cent of healthcare workers experiencing at least one stressful occurrence annually.
The use of safety needles in healthcare settings offers numerous cost benefits. They reduce healthcare worker injuries, lowering costs from potential disease treatment and potential long-term health issues. By minimising needle stick injuries, they also decrease expenses for post-exposure prophylaxis and associated healthcare costs. Moreover, safety needles mitigate compensation claims, absenteeism, and can lead to lower health insurance premiums, while Dispojekt also reduces product and packaging footprint for cost and environmental savings.
They assist in creating a safer and more reliable workplace environment for healthcare workers.
Dispojekt single use syringe with safety needle looks very simply, it’s a two-part plastic component assembled with a cannula to make a needle like a conventional needle. However, the first idea came across to us from our associate in Germany and in England, was of a needle with a safety cover, but was quite expensive to mold and even more expensive to assemble.
There was no point to introduce a product in the market which will be very expensive and not very competitive and will also have a huge challenge in production capacity. So, we gave back the challenge to the designers. The molded component was designed to be less complicated, be more equipped for mass manufacturing and by redesigning, achieving that, we were able to attain a technology that would be more cost effective.
After clinical evaluation of Dispojekt in laboratories at England and in clinical settings, video shots of the products were taken in slow speed and high speed. It was found that when the shield was closing, it was striking the needle strongly resulting in blood splatter. The hinge was redesigned to ensure a soft closure to avoid any blood splatter from taking place, thereby avoiding any aerosols or contamination in the environment.
All these iterations took 4 years to incorporate in the product design.
In the ever-evolving landscape of healthcare, ensuring the safety of both patients and healthcare workers remains paramount and to address wish list of WHO for a SMART safety engineered syringes that incorporate both Auto Disabling Reuse prevention features (to protect patients) as well as Needle Stick Prevention features (that protects healthcare workers)
HMD is now readying itself to provide a smart syringe to the world viz KOJAK SMART SYRINGES. A smart syringe combines the proven efficacy of auto-disable syringes with the added safeguard of a hinged needle cover, this next-generation medical device represents a significant leap forward in safety engineering. Designed to address the dual challenge of preventing needlestick injuries and reducing the risk of syringe reuse, these syringes offer a comprehensive solution that prioritizes both patient and healthcare worker safety.